Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Zevra Therapeutics Inc ZVRA

Healthcare
Zevra Therapeutics, Inc. is a rare disease company science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ZVRA)

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

Accesswire 7 hours ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

Newsfile 4 days ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

PR Newswire 6 days ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

Accesswire 8 days ago

Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting

GlobeNewswire 10 days ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

Newsfile 12 days ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

PR Newswire April 12, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

Accesswire April 10, 2024

Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility

GlobeNewswire April 10, 2024
View More News ››

Opinion & Analysis (NDAQ:ZVRA)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ZVRA)

RE:Support?

Lisagerrard17 - June 6, 2022

RE:RE:RE:RE:RE:RE:RE:RE:Support?

Congrats!    What a day.   I have been buying the dips.   I will be holding this for a bit here.
mevani - March 3, 2021

RE:RE:RE:RE:RE:RE:RE:Support?

After approval with 30/13 label I can see a buyout by GPC and that could cost them $3 billion. It's not just a drug with the same...
Bobby90 - February 11, 2021

RE:RE:RE:RE:RE:RE:Support?

Sounds good......in the mean time..... I just take profits when they stare me in the face.  Good luck to you!  Cheers ...
Iseneschal - February 4, 2021

RE:RE:RE:RE:RE:Support?

If GPC buys them out then we can expect a share price of $30 minimum. New River Pharmaceuticals (Vyvanse) got bought out before approval...
Bobby90 - February 4, 2021

RE:RE:RE:RE:Support?

Still in play.......added a small position.  Cheers !
Iseneschal - February 4, 2021
View more Bullboard ››

Northstar Gold Corp.

Northstar Gold Corp.

Northstar Gold Corp is a Canada-based company, which is focused on the exploration, development, and acquisition of ...
View More »